An Open-Label, Safety, Tolerability and Efficacy Study of Vaginal AZU-101 in Postmenopausal Women
Latest Information Update: 12 Jan 2024
At a glance
- Drugs Lasofoxifene (Primary)
- Indications Atrophic vaginitis
- Focus Adverse reactions
- Sponsors Azure Biotech
Most Recent Events
- 12 Jan 2024 New trial record